SCHEMBL13755200

SCHEMBL13755200

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(Br)cc32)c(C)c1C(=O)NCCN(C)C

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 14/20 0.84
PDGFRB P09619 7/20 0.84
FGFR1 P11362 5/20 0.84
EGFR P00533 3/20 0.84
PRKAA1 Q13131 13/20 0.80
PRKAA2 P54646 12/20 0.80
FLT3 P36888 3/20 0.67
PLK4 O00444 2/20 0.67
DCLK1 O15075 2/20 0.67
PDPK1 O15530 2/20 0.67
DAPK3 O43293 2/20 0.67
ROCK2 O75116 2/20 0.67
RPS6KA5 O75582 2/20 0.67
RPS6KA4 O75676 2/20 0.67
MAP4K4 O95819 2/20 0.67
CHEK2 O96017 2/20 0.67
NTRK1 P04629 2/20 0.67
INSR P06213 2/20 0.67
LCK P06239 2/20 0.67
FYN P06241 2/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2115889 1.00 KDR (0.84) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL31672480 0.91 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL5831195 0.91 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL2116962 0.91 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL905668 0.89 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL2113942 0.89 KDR (0.84) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL31672439 0.89 KDR (0.84) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL29856494 0.89 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL13755223 0.89 KDR (0.84) KDRPDGFRBFGFR1EGFRPRKAA1
SCHEMBL905672 0.89 KDR (1.00) KDRPDGFRBFGFR1EGFRPRKAA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 US disclosed
US-7572924-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2009-08-11 US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 US disclosed
US-7320996-B2 Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer SUGEN, INC (US) 2008-01-22 US disclosed
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2007-01-11 US disclosed
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. & PHARMACIA & UPJOHN CO. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010569-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors PDPK1, PLK2, PNCK KDR 1387/4885PDGFRB 1034/4885FGFR1 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.